In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2

International Journal of Cancer

Volumn 113, Issue 6, 2005, Pages 937-945

  Kis, Loránd L ^a   Nishikawa, Jun ^a,d   Takahara, Miki ^a   Nagy, Noémi ^a   Matskova, Liudmila ^a   Takada, Kenzo ^b   Elmberger, P Göran ^c   Ohlsson, Ann ^c   Klein, George ^a   Klein, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HOKKAIDO UNIVERSITY   (Japan)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Epstein Barr virus; Hodgkin lymphoma; Latent membrane protein 1

Indexed keywords

AZACITIDINE; BUTYRIC ACID; CD40 LIGAND; GENOMIC DNA; INTERLEUKIN 4; LATENT MEMBRANE PROTEIN 1; PHORBOL 13 ACETATE 12 MYRISTATE; TRICHOSTATIN A;

ARTICLE; B LYMPHOCYTE; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; VIRUS DETECTION; VIRUS INFECTION;

BACTERIAL OUTER MEMBRANE PROTEINS; CD40 LIGAND; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; INTERLEUKIN-4; VIRAL PROTEINS;

EID: 19944429671     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20654     Document Type: Article

References (49)

1. Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res 2002;84:277-312.
2. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-12.
3. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-505.
4. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-97.
5. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 2003;45:1-36.
6. Herbst H. Epstein-Barr virus in Hodgkin's disease. Semin Cancer Biol 1996;7:183-9.
7. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;337:320-2.
8. Niedobitek G, Kremmer E, Herbst H, Whitehead L, Dawson CW, Niedobitek E, von Ostau C, Rooney N, Grasser FA, Young LS. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 1997;90:1664-72.
9. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82.
10. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, Tursz T, Kallin B. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329-38.
11. Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang JS, Madsen M, Rosdahl N, Konradsen HB, Storm HH, Melbye M. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003;349:1324-32.
12. Drexler HG. The leukemia-lymphoma cell lines facts book. San Diego, CA: Academic Press, 2000.
13. Staratschek-Jox A, Wolf J, Diehl V. Hodgkin's disease. In: Masters JRW, Palsson B, eds. Human cell culture. vol. 3. Lymphoma and leukemia cell lines. Dordrecht: Kluwer Academic Press, 2000. 339-53.
14. Kis LL, Nagy N, Klein G, Klein E. Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines. Int J Cancer 2003;104:658-61.
15. Maeda A, Kiss C, Chen F, Ehlin-Henriksson B, Nagy N, Szekely L, Takada K, Klein E, Klein G. EBNA promoter usage in EBV-negative Burkitt lymphoma cell lines converted with a neomycin-resistant EBV strain. Int J Cancer 2001;93:714-9.
16. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 2002;8:594-9.
17. Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 1973;11:499-520.
18. Just T, Burgwald H, Broe MK. Flow cytometric detection of EBV (EBER snRNA) using peptide nucleic acid probes. J Virol Methods 1998;73:163-74.
19. Nishikawa J, Kis LL, Liu A, Zhang X, Takahara M, Bandobashi K, Kiss C, Nagy N, Okita K, Klein G, Klein E. Upregulation of LMP1 expression by histone deacetylase inhibitors in an EBV carrying NPC cell line. Virus Genes 2004;28:121-8.
20. Di Renzo L, Avila-Carino J, Klein E. Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules. Immunol Lett 1993;38:207-14.
21. Cuomo L, Trivedi P, de Campos-Lima PO, Zhang QJ, Ragnar E, Klein G, Masucci MG. Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines. Mol Immunol 1993;30:441-50.
22. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995;147:912-22.
23. Poppema S, Potters M, Emmens R, Visser L, van den Berg A. Immune reactions in classical Hodgkin's lymphoma. Semin Hematol 1999;36:253-9.
24. Nagy N, Maeda A, Bandobashi K, Kis LL, Nishikawa J, Trivedi P, Faggioni A, Klein G, Klein E. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is down-regulated in parallel with immunoblastic transformation. Int J Cancer 2002;100:433-40.
25. Diehl V, Kirchner HH, Burrichter H, Stein H, Fonatsch C, Gerdes J, Schaadt M, Heit W, Uchanska-Ziegler B, Ziegler A, Heintz F, Sueno K. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep 1982;66:615-32.
26. Vockerodt M, Beige G, Kube D, Irsch J, Siebert R, Tesch H, Diehl V, Wolf J, Bullerdiek J, Staratschek-Jox A. An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591. Br J Haematol 2002;119:640-6.
27. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 2002;21:4908-20.
28. Arguello M, Sgarbanti M, Hernandez E, Mamane Y, Sharma S, Servant M, Lin R, Hiscott J. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene 2003;22:964-73.
29. Loddenkemper C, Anagnostopoulos I, Hummel M, Johrens-Leder K, Foss HD, Jundt F, Wirth T, Dorken B, Stein H. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004;202:60-9.
30. Tierney R, Kirby H, Nagra J, Rickinson A, Bell A. The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J Virol 2000;74:10458-67.
31. Contreras-Brodin B, Karlsson A, Nilsson T, Rymo L, Klein G. B cell-specific activation of the Epstein-Barr virus-encoded C promoter compared with the wide-range activation of the W promoter. J Gen Virol 1996;77:1159-62.
32. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JL. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993;81:1393-403.
33. Oudejans JJ, Jiwa M, van den Brule AJ, Grasser FA, Horstman A, Vos W, Kluin PM, van der Valk P, Walboomers JM, Meijer CJ. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 1995;147:923-33.
34. Zettl A, Lee SS, Rudiger T, Starostik P, Marino M, Kirchner T, Ott M, Muller-Hermelink HK, Ott G. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002;117:368-79.
35. Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, Knowles DM, Cesarman E. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 1997;90:1186-91.
36. Trivedi P, Takazawa K, Zompetta C, Cuomo L, Anastasiadou E, Carbone A, Uccini S, Belardelli F, Takada K, Frati L, Faggioni A. Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood 2004;103:313-6.
37. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, Huhn D, Schmidt-Westhausen A, Reichart PA, Gross U, Stein H. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-20.
38. Contreras-Brodin BA, Anvret M, Imreh S, Altiok E, Klein G, Masucci MG. B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids. J Gen Virol 1991;72:3025-33.
39. Altmeyer A, Simmons RC, Krajewski S, Reed JC, Bornkamm GW, Chen-Kiang S. Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation. Immunity 1997;7:667-77.
40. Wendel-Hansen V, Rosen A, Klein G. EBV-transformed lymphoblastoid cell lines down-regulate EBNA in parallel with secretory differentiation. Int J Cancer 1987;39:404-8.
41. Brauninger A, Spieker T, Mottok A, Baur AS, Kuppers R, Hansmann ML. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Eur J Immunol 2003;33:1593-602.
42. Brauninger A, Spieker T, Willenbrock K, Gaulard P, Wacker HH, Rajewsky K, Hansmann ML, Kuppers R. Survival and clonal expansion of mutating "forbidden" (immunoglobulin receptor-deficient) Epstein-Barr virus-infected B cells in angioimmunoblastic T cell lymphoma. J Exp Med 2001;194:927-40.
43. Xu WS, Chan AC, Lee JM, Liang RH, Ho FC, Srivastava G. Epstein-Barr virus infection and its gene expression in gastric lymphoma of mucosa-associated lymphoid tissue. J Med Virol 1998;56:342-50.
44. Adler B, Schaadt E, Kempkes B, Zimber-Strobl U, Baier B, Bornkamm GW. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci USA 2002;99:437-42.
45. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol 2003;77:8532-40.
46. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-9.
47. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997;182:151-9.
48. Kurth J, Hansmann ML, Rajewsky K, Kuppers R. Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci USA 2003;100:4730-5.
49. Teramoto N, Gogolak P, Nagy N, Maeda A, Kvarnung K, Bjorkholm T, Klein E. Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle. J Hum Virol 2000;3:125-36.